Dermatology Times
DECEMBER 15, 2023
Roflumilast foam 0.3% is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.
Lipgloss and Aftershave
DECEMBER 15, 2023
Roccoco Botanicals is a brand that we’ve known for years. We featured their GloBiotic Serum and VitaSkin in 2019. We reconnected in early 2023 and featured their Frangipani and Lychee Body Creme in our Get Fit Be Well Guide ! Then, in the fall of 2023, we learned that the brand had been given some high level recognition. Roccoco founder, Jacine Drummond, has a bit of a reputation on the global skincare scene as being a bit of a genius!
Dermatology Times
DECEMBER 15, 2023
ICYMI, this week we had articles about coverage from the Revolutionizing Atopic Dermatitis and Vitiligo virtual conferences, expert insights on AAD's updated AD management guidelines, positive data of axitinib for basal cell carcinoma, and more.
The Dermatology Digest
DECEMBER 15, 2023
A novel, low-cost hydrogel using a component found in seaweed may aid wound healing, according to new research in the International Journal of Biological Macromolecules. The hydrogel was made using alginate, calcium carbonate, and carbonated water. Alginate is a biocompatible substance that can be extracted from beach-cast seaweed that does not adhere strongly to cells or skin tissues.
Dermatology Times
DECEMBER 15, 2023
A poster from the RAD Virtual Conference reviewed the relationship between Black and DHH patients and the shared disparities these populations face.
The Dermatology Digest
DECEMBER 15, 2023
By Denise Mann, MS By all accounts, 2023 was a banner year in dermatology, and 2024 is looking equally as bright, according to top key opinion leaders. Here, Derm Digest looks back on the new approvals, breakthrough bench research, and other hot topics in cutaneous diseases from 2023. AD: New topicals for kids “The most exciting new research is in the realm of topical therapies for atopic dermatitis (AD) in children,” shares Peter A.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
The Dermatology Digest
DECEMBER 15, 2023
Contrary to concerns regarding malignancy, venous thromboembolism, and major adverse cardiac events, the use of Janus kinase (JAK) inhibitors is not associated with a significant increase in the overall risk for these conditions in patients with atopic dermatitis (AD), according to a systematic review and meta-analysis , published in the Journal of the European Academy of Dermatology & Venereology.
Dermatology Times
DECEMBER 15, 2023
Adbry (tralokinumab-LDRM) is now the first and only FDA-approved biologic for AD binding to and inhibiting IL-13.
The Dermatology Digest
DECEMBER 15, 2023
By Denise Mann, MS By all accounts, 2023 was a banner year in dermatology, and 2024 is looking equally as bright, according to top key opinion leaders. Here, Derm Digest looks back on the new approvals, breakthrough bench research, and other hot topics in cutaneous diseases from 2023. AD: New topicals for kids “The most exciting new research is in the realm of topical therapies for atopic dermatitis (AD) in children,” shares Peter A.
Dermatology Times
DECEMBER 15, 2023
The emergence of JAK inhibitors has shown tremendous promise as a novel therapeutic approach.
The Dermatology Digest
DECEMBER 15, 2023
Contrary to concerns regarding malignancy, venous thromboembolism, and major adverse cardiac events, the use of Janus kinase (JAK) inhibitors is not associated with a significant increase in the overall risk for these conditions in patients with atopic dermatitis (AD), according to a systematic review and meta-analysis , published in the Journal of the European Academy of Dermatology & Venereology.
Dermatology Times
DECEMBER 15, 2023
The confirmatory phase 3 trial demonstrated significant efficacy of TO-208 versus a placebo.
The Dermatology Digest
DECEMBER 15, 2023
A novel, low-cost hydrogel using a component found in seaweed may aid wound healing, according to new research in the International Journal of Biological Macromolecules. The hydrogel was made using alginate, calcium carbonate, and carbonated water. Alginate is a biocompatible substance that can be extracted from beach-cast seaweed that does not adhere strongly to cells or skin tissues.
Dermatology Times
DECEMBER 15, 2023
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had in managing the disease.
Art of Dermatology
DECEMBER 15, 2023
When selecting a dermatologist in New York City, it is important to look for an office with a board-certified dermatologist, and to make sure that is who you are actually seeing for your appointment. Choosing a board-certified dermatologist can ensure that you receive the most accurate diagnosis, the most efficient treatment, and the best cosmetic outcomes.
Dermatology Times
DECEMBER 15, 2023
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the current treatment landscape of atopic dermatitis (AD), as well as key factors when selecting treatment for patients with the disease.
US Dermatologt Partners
DECEMBER 15, 2023
U.S. Dermatology Partners is your specialty dermatologist in Kaufman, Texas. We offer treatment for acne, eczema, skin cancer, & more.
The Dermatology Digest
DECEMBER 15, 2023
Global warming and other environmental changes may be contributing to rising rates of epithelial barrier dysfunction and atopic dermatitis (AD). This is among the main messages from research published in a themed issue of Annals of Allergy, Asthma & Immunology. When the epithelial barrier is disrupted, it facilitates the entry of the external exposome into and underneath the epithelium, triggering an expulsion response driven by inflammatory cells in the area, and leading to chronic inflamm
US Dermatologt Partners
DECEMBER 15, 2023
U.S. Dermatology Partners is trusted for Mohs and Plastic Surgery in Peoria, Arizona. We offer surgical treatments for skin cancer.
The Dermatology Digest
DECEMBER 15, 2023
The U.S. Food and Drug Administration (FDA) has given its nod to topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis. The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. Arcutis aims to make the foam widely available via wholesaler and dermatology pharmacy channels by the end of January 2024. “This is a once-daily non-steroidal treatment that doesn’t have any duration on use,” Patrick Burne
Aesthetics Advisor
DECEMBER 15, 2023
A cancer diagnosis can trigger terror or an instinctive battle response. The urge to do something—anything—can be overpowering. The urge to fight cancer aggressively fuels a multi-billion dollar industry in the United States. Millions undergo treatments with limited effectiveness, preferring action over the potentially more healthful option of “watchful waiting.
The Dermatology Digest
DECEMBER 15, 2023
The U.S. Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the first and only FDA-approved biologic that specifically binds to and inhibits the interleukin (IL)-13 cytokine.
The Dermatology Digest
DECEMBER 15, 2023
The U.S. Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the first and only FDA-approved biologic that specifically binds to and inhibits the interleukin (IL)-13 cytokine.
The Dermatology Digest
DECEMBER 15, 2023
The U.S. Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the first and only FDA-approved biologic that specifically binds to and inhibits the interleukin (IL)-13 cytokine.
Expert insights. Personalized for you.
74 
Let's personalize your content